Alpha Tau Medical (DRTS)
(Delayed Data from NSDQ)
$2.83 USD
+0.16 (5.99%)
Updated May 17, 2024 04:00 PM ET
After-Market: $2.74 -0.09 (-3.18%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DRTS 2.83 +0.16(5.99%)
Will DRTS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DRTS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DRTS
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?
Best Momentum Stocks to Buy for January 8th
DRTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 8th
Down -20.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Tau Medical Ltd. (DRTS)
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
Other News for DRTS
Innovative Alpha DaRT Cancer Treatment Promises Broad Usability and Efficacy, Merits Buy Rating
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
Alpha Tau announces Alpha DaRT treatment of first patient with liver cancer
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
Alpha Tau presents preclinical data at 2024 ESTRO